Late-night biotech lab, monitor shows Mendus financial data with declining cash on hand.
Unprofitable biopharmaceutical company Mendus (STO:IMMU) is staring down an urgent financial challenge, with analysis from Simply Wall St revealing a precarious cash runway. As of March 2026, Mendus held kr74 million in cash, but its cash burn over the preceding year hit kr87 million, leaving it with an estimated cash runway of just 10 months. This short timeline underscores a critical need for the company to either drastically reduce spending or secure substantial new funding.
The situation is compounded by an accelerating burn rate. Mendus’s cash burn increased by 35% in the last year, indicating a heightened investment in future growth. While such spending can signal ambition, for a company currently generating no revenue, it directly shortens the time before more capital is required. Simply Wall St highlights that covering another year’s operations at the current burn rate (kr87 million) would necessitate raising capital equivalent to approximately 24% of its kr368 million market capitalization. This level of fundraising would inevitably lead to significant shareholder dilution, posing a considerable risk to existing investors.
For startup founders and investors watching the biotech space, Mendus’s predicament serves as a stark reminder of the delicate balance between growth investment and financial stability. The company’s immediate future hinges on its ability to navigate this cash crunch, either through strategic operational adjustments or by successfully attracting new capital without overly diluting its current ownership structure.
About the Author
